A1C (glycated hemoglobin)
How GLP-1 receptor agonists work — receptors, gastric emptying, and the satiety pathway.
Definition
A blood test reflecting average blood glucose over the prior 8-12 weeks, measured as the percentage of red-blood-cell hemoglobin glycated by glucose. Used as the primary endpoint in T2D trials. Diagnostic threshold: ≥6.5% = diabetes; 5.7-6.4% = prediabetes; <5.7% = normal. GLP-1 receptor agonists typically reduce A1C by 1.0-2.0 percentage points at maximum dose — clinically meaningful, because each 1-point drop reduces microvascular complication risk roughly 25-35%.
Definition curated by Weight Loss Rankings — sourced from FDA labels and peer-reviewed PubMed literature, never AI-generated summaries.
Related terms in Mechanism
- GLP-1 receptor
- GIP receptor
- Dual agonist
- Gastric emptying
- Food noise
- Triple agonist
- Amylin
- GLP-1 tachyphylaxis
- Non-peptide GLP-1 agonist
- MASH / MASLD
- TBWL (Total Body Weight Loss)
- C-peptide
- eGFR (estimated glomerular filtration rate)
- Visceral adipose tissue (VAT)
- AHI (apnea-hypopnea index)
- SNAC (oral semaglutide absorption enhancer)
Looking for more depth?
- GLP-1 trial reading list
- Browse the full GLP-1 glossary (124 terms across 8 categories)
- Research articles — primary-source deep dives
- Tools and calculators
- Compare GLP-1 telehealth providers